KRENSAVAGE ASSET MANAGEMENT LLC
Q1 2022 Form 13-F
NEW YORK, NEW YORK
CIK 0001609251
· CRD 168976
· SEC-registered investment adviser
$290.1M Reported Value Total
KRENSAVAGE ASSET MANAGEMENT, LLC reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $314,669,759, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
3 funds
· $393.8M gross asset value
Hedge Fund: $393.8M
Source: Form ADV filed 2026-03-25
Reported value
$290.1M
Quarter over quarter
+2.9%
Holdings
13
Top-10 concentration
99.7%
Key People
Form ADV owners & control persons
Michael Paul Krensavage
MANAGING MEMBER/CHIEF EXECUTIVE OFFICER
Paul Joseph Paolino
CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2022 13F record
Q1 2022 13F filing summary
| Period of report | March 31, 2022 |
|---|---|
| Filed | May 17, 2022 |
| Form | 13F-HR |
| Reported value | $290.1M |
| Positions | 13 |
| Change in reported value | +0.6% |
| New positions | 3 |
| Exited positions | 0 |
| Position turnover | 23.1% |
| Top-10 concentration | 99.7% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
18 | $263.2M |
|
Q1 2026 13F
Filed May 15, 2026
|
20 | $255.7M |
|
Q4 2025 13F
Filed Feb 18, 2026
|
18 | $283.1M |
|
Q3 2025 13F
Filed Nov 17, 2025
|
17 | $234.7M |
|
Q2 2025 13F
Filed Aug 15, 2025
|
15 | $188.9M |
|
Q1 2025 13F
Filed May 15, 2025
|
14 | $180.9M |
|
Q4 2024 13F
Filed Feb 18, 2025
|
12 | $169.0M |
|
Q3 2024 13F
Filed Nov 15, 2024
|
13 | $178.5M |
|
Q2 2024 13F
Filed Aug 15, 2024
|
13 | $217.8M |
|
Q1 2024 13F
Filed May 15, 2024
|
12 | $225.5M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
12 | $281.9M |
|
Q3 2023 13F
Filed Nov 15, 2023
|
12 | $271.6M |
|
Q2 2023 13F
Filed Aug 11, 2023
|
12 | $315.6M |
|
Q1 2023 13F
Filed May 16, 2023
|
12 | $329.3M |
|
Q4 2022 13F
Filed Feb 15, 2023
|
12 | $323.6M |
|
Q3 2022 13F
Filed Nov 15, 2022
|
14 | $314.1M |
|
Q2 2022 13F
Filed Aug 16, 2022
|
14 | $302.5M |
|
Q1 2022 13F
Filed May 17, 2022
|
13 | $290.1M |
|
Q4 2021 13F
Filed Feb 15, 2022
|
10 | $288.3M |
|
Q3 2021 13F
Filed Nov 16, 2021
|
13 | $318.8M |
27 earlier quarters on file — choose one from the quarter menu above.
Top 13 holdings · Q1 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | REGN REGENERON PHARMACEUTICALS | $46.7M | 16.1% |
| 2 | ENTA ENANTA PHARMACEUTICALS INC | $39.1M | 13.46% |
| 3 | MCK MCKESSON CORP | $38.0M | 13.1% |
| 4 | ALKS ALKERMES PLC | $37.5M | 12.92% |
| 5 | UTHR UNITED THERAPEUTICS CORP | $36.2M | 12.47% |
| 6 | EXEL EXELIXIS INC | $34.7M | 11.96% |
| 7 | TARO TARO PHARMACEUTICAL INDUS | $24.5M | 8.44% |
| 8 | BIIB BIOGEN INC | $23.5M | 8.08% |
| 9 | EGRX EAGLE PHARMACEUTICALS INC | $5.7M | 1.96% |
| 10 | KOD KODIAK SCIENCES INC | $3.5M | 1.2% |
| 11 | CAH CARDINAL HEALTH INC | $748.0K | 0.26% |
| 12 | NXTC NEXTCURE INC | $149.0K | 0.05% |
| 13 | ASMB ASSEMBLY BIOSCIENCES INC | $21.0K | < 0.01% |
Values as reported on the Q1 2022 Form 13F. Every position is in the holdings table below.